Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LMTX

- PMLiVE

New study finds brains of ‘superagers’ contain larger neurones in memory region

Superagers had 'significantly larger' brain cells in a region of the brain that is critical for memory

- PMLiVE

Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study

Results from the phase 3 trial showed reduction in clinical decline

- PMLiVE

Alzheimer’s Research UK announces ‘record’ financial performance for 2021/22

The charity was forced to put much of its activity on hold due to the COVID-19 pandemic

- PMLiVE

Lilly’s Retevmo approved by FDA for RET fusion+ advanced/metastatic solid tumours

Results demonstrated an overall response rate of 44% across multiple tumour types

- PMLiVE

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

- PMLiVE

AbbVie’s Imbruvica bags FDA approval for paediatric patients with chronic graft versus host disease

The decision marks the first approved treatment for children with the condition under 12 years

- PMLiVE

Alpha Cognition announces positive results for Alzheimer’s disease treatment

The number of people with dementia is predicted to increase to around one million by 2025, increasing to 1.6 million by 2040

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn

The agreement will focus on drug discovery, development and commercialisation of neurological diseases

- PMLiVE

Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer’s disease

Eisai presented the data at the Alzheimer’s Association International Conference (AAIC)

- PMLiVE

Eli Lilly to make bebtelovimab commercially available to US states from August

The COVID-19 antibody is expected to become commercially available prior to the anticipated depletion of the US government’s current available supply

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links